Eli Lilly and Company (LLY)
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study
A drug combination studied in people with Type 2 diabetes lowered blood sugar and helped people lose more weight than with Zepbound alone.
Prediction: Eli Lilly's Next Growth Wave Could Surprise Investors
Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions.
Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200
The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the needle on a stock already up 60% and closing in on record highs.
TRex Bio Files For IPO As Collaboration With Eli Lilly Deepens
TRex Bio is a clinical-stage biopharma targeting autoimmune and inflammatory diseases, with a lead program in Phase 1b trials for treating atopic dermatitis. TRXB's deepening collaboration with Eli Lilly, including milestone payments and potential IPO participation, signals strong strategic backing and validation. The company is well-capitalized, with a high-quality and diverse investor syndicate, but will require further funding beyond the IPO.
FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes
The once-weekly treatment could reduce the number of injections by more than 300 per year compared with once-daily basal insulin, Eli Lilly said.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
There Are Plenty of Eli Lilly Bulls: Here's What They Aren't Telling You
Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded with blockbuster candidates, but there are a few uncomfortable details quietly buried in the earnings report that change how the story reads.
Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030
Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be sharper. One company is compounding a franchise that keeps widening, while the other is racing to patch a hole before a patent cliff arrives.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.99% move from its prior day's close.
Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets
Eli Lilly and Company NYSE: LLY is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company's executive vice president and president of Lilly USA and Global Customer Capabilities.
